Dr. Rahul Davé is a specialty care physician board certified in neurology at Inova Health System. He joined Inova Neurology in 2017. He specializes in the treatment of multiple sclerosis, neuromyelitis optica (NMO), optic neuritis, transverse myelitis, neuro-sarcoid, neurologic complications of rheumatologic diseases, autoimmune encephalitis, PML, inflammatory neuropathies, myasthenia gravis, paraneoplastic disorders, vasculitis and neuro-infectious diseases (including Lyme).
He is the Medical Director of the interdisciplinary Inova Multiple Sclerosis and Neuro-Immunology Center, which is recognized by the Consortium of Multiple Sclerosis Centers and is also a recipient of a "Partner" award by the National Multiple Sclerosis Society.
He lectures broadly about multiple sclerosis and related diseases, teaches students, conducts research and serves as an expert consultant for the development of novel therapeutics. Current research interests include anti-MOG syndrome and novel therapeutics for neuro-inflammatory disorders.
Prior to joining Inova, Dr. Davé worked at the National Institutes of Health (NIH), where he evaluated complicated multiple sclerosis patients and participated in the Undiagnosed Diseases Program, and conducted several clinical trials and laboratory research. He continues to maintain a Special Volunteer appointment at NIH where his research focus is Erdheim-Chester Disease.
Dr. Davé became interested in neurology because family members struggled with neurologic diseases. His goal is to allow his patients to lead active lives by helping them understand and treat their diseases.
Having lived all over the United States of America, Dr. Davé and his wife fell in love with the Washington, DC metro region. They currently reside in Bethesda, MD. In his spare time he likes to hike, cook and garden.
- American Academy of Neurology
Published Blog Articles and Other Media
Three part series: Understanding Multiple Sclerosis: A Primer for the Newly Diagnosed
Rachelle Defies MS with Strength and Medical partnership, June 2022